PCVX

Vaxcyte, Inc. (PCVX) - Q2 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2026. Vaxcyte, Inc. is a clinical-stage vaccine innovation company utilizing its proprietary XpressCF cell-free protein synthesis platform to develop high-fidelity vaccines against bacterial diseases. The company has no products approved for commercial sale and currently generates no product revenue. Its primary focus is the development of its pneumococcal conjugate vaccine (PCV) franchise, specifically VAX-31 and VAX-24.

Key Financial Metrics

Material Changes vs. Prior Period

• Increased Operating Expenses: Total operating expenses increased by 33.8% ($76.6 million) in Q2 2026 compared to Q2 2025, and by 59.4% ($241.6 million) on a year-to-date basis. This was driven primarily by a 37.9% increase in R&D expenses due to expanded clinical trial activities (specifically the VAX-31 Phase 3 program) and increased product manufacturing costs.
• Reduced Other Income: Total other income, net decreased by 69.0% in Q2 2026 compared to the prior year period. This decline was primarily attributable to a $35.9 million reduction in unrealized and realized foreign currency gains and a $5.3 million decrease in interest income due to lower cash balances and interest rates.
• Capital Raise: In February 2026, the company completed an underwritten public offering of 12.65 million shares, raising approximately $601.8 million in net proceeds. This significantly bolstered liquidity compared to the prior year period which had no such offering.

Outlook, Management Commentary, and Risks

• Clinical Progress:
  • VAX-31 (Adults): All three Phase 3 trials (OPUS-1, OPUS-2, OPUS-3) are fully enrolled with 6,191 adults dosed. Topline data for OPUS-1 is expected in Q4 2026, with OPUS-2 and OPUS-3 data expected in H1 2027.
  • VAX-31 (Pediatrics): Enrollment in the Phase 2 infant study was completed in January 2026. Topline data is expected by the end of H1 2027.
  • VAX-A1: Initiated a Phase 1 adult study for Group A Strep in June 2026.
• Liquidity: Management believes existing cash, cash equivalents, and investments ($2.5 billion) are sufficient to fund operations and capital expenditures for at least 12 months from the filing date.
• Manufacturing: A dedicated commercial manufacturing suite at Lonza in Switzerland was handed over for operation on August 1, 2026. The company also has a commercial supply agreement with Thermo Fisher Scientific.
• Risks: Key risks include the failure of clinical trials to meet endpoints, delays in regulatory approval, the high cost of development, reliance on third-party manufacturers, and the need for substantial additional capital to achieve profitability. The company has no revenue and expects to incur significant losses for the foreseeable future.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $2.5 billion cash position against the accelerating burn rate (net loss of $604.9 million YTD) to confirm the 12-month liquidity assertion.
• Phase 3 Enrollment: Confirm the status of the 6,191 enrolled adults in the VAX-31 Phase 3 trials and the timeline for the Q4 2026 topline data readout.
• Manufacturing Readiness: Assess the operational status of the Lonza facility (handed over August 1, 2026) and the Thermo Fisher agreement to ensure supply chain readiness for potential commercial launch.
• Capital Requirements: Evaluate the company's plan for future financing given the substantial accumulated deficit ($2.8 billion) and the high cost of scaling manufacturing and commercial infrastructure.
• Competitive Landscape: Monitor competitor activities, specifically Pfizer's PCV25 and Merck's PCV21, which may impact Vaxcyte's market opportunity.